In May 2024, we adopted and announced a targeted restructuring plan (the "Restructuring Plan"). This plan includes a strategic shift in our approach to the Healthcare surgical business in Europe, as well as other actions including the impairment of an internally developed X-ray accelerator, product rationalizations and facility consolidations. Approximately 300 positions have been eliminated. These restructuring actions were designed to enhance profitability and improve efficiency. As of March 31, 2026, the execution of our Restructuring Plan is substantially complete.

The following table summarizes our total pre-tax restructuring expenses recorded in fiscal 2026 and 2025 related to the Restructuring Plan:


(in millions)
Restructuring Plan
Years Ended March 31,	2026		2025		2024
Severance and other compensation related costs	$	2.6	$	29.0	$	0.7
Lease and other contract termination and other costs	1.5		12.4		—
Product rationalization (1)	(0.7)		16.2		18.3
Accelerated depreciation and amortization and asset impairment	—		4.7		25.4
Total Restructuring Expense	$	3.4	$	62.3	$	44.4

The Restructuring Plan expenses incurred during fiscal 2026 and 2025 primarily related to actions taken in our Healthcare and AST segments. Total pre-tax restructuring expense of $110.1 million has been recorded relating to the Restructuring Plan since inception, of which $33.9 million has been recorded in Cost of revenues.

Liabilities related to restructuring activities are recorded as current liabilities in the accompanying Consolidated Balance Sheets within "Accrued payroll and other related liabilities" and "Accrued expenses and other." The following table summarizes our restructuring liability balances:



(in millions)	Restructuring Plan
Balance at March 31, 2024	$	0.7
Fiscal 2025 charges	41.4
Payments	(23.7)
Balance at March 31, 2025	$	18.4
Fiscal 2026 charges	4.1
Payments	(15.4)
Balance at March 31, 2026	$	7.1